title: Therapeutic Approaches to RAS Mutation.
abstract: The study of oncogenic RAS mutations has led to crucial discoveries regarding cancer molecular biology and behavior and has been integral in shaping the era of targeted cancer therapy. RAS mutations are one of the most common oncogenic drivers in human cancer, and intense efforts to find a clinically effective inhibitor are ongoing. Despite these efforts, targeting RAS mutations has remained elusive, so much so that some have termed oncogenic RAS mutations as "undruggable." In this review, we will summarize current understanding of RAS biology, explore strategies to inhibit RAS oncoproteins and its downstream effectors, and discuss recently described complexities that have shed new light on this pursuit.
authors.affiliation: From the Division of Medical Oncology, University of Colorado Denver Anschutz Medical Campus, and University of Colorado Cancer Center, Aurora, CO.
authors.forename: Aaron J
authors.initials: AJ
authors.lastname: Scott
authors.forename: Christopher H
authors.initials: CH
authors.lastname: Lieu
authors.forename: Wells A
authors.initials: WA
authors.lastname: Messersmith
mesh_terms: D000818:Animals; D006801:Humans; D058990:Molecular Targeted Therapy; D009154:Mutation; D009369:Neoplasms / Q000188:drug therapy* / Q000235:genetics* / Q000378:metabolism; D011485:Protein Binding; D020033:Protein Isoforms; D011499:Protein Processing, Post-Translational; D018631:ras Proteins / Q000737:chemistry / Q000235:genetics* / Q000378:metabolism
chemical_list: D020033:Protein Isoforms; D018631:ras Proteins